VIDD’s goal is to eliminate or reduce the mortality and morbidity of infectious diseases.
The Vaccine and Infectious Disease Division (VIDD) was established as an institute at Fred Hutchinson Cancer Research Center in 2007 to facilitate and enhance the Center’s efforts in infectious disease prevention and vaccine development. The institute achieved Division status in 2010.
The Division has more than 50 faculty members. VIDD faculty lead the HIV Vaccine Trials Network (HVTN) - the world’s largest clinical trials network for the development and testing of an HIV vaccine. Division faculty members are also studying cancer-associated infections such as herpesvirus-8, as well as common pathogens including herpes simplex viruses, cytomegalovirus and infectious fungi. Our scientists fall into three broad research disciplines:
- Infectious Diseases Sciences
- Immunology and Vaccine Development
- Population Sciences
VIDD research programs integrate the latest in computational, laboratory and clinical research methods to advance the understanding of microbial pathogenesis and infectious disease processes. VIDD researchers partner with scientists at laboratory, clinical and field sites in Africa, Asia and Europe. The Division has specific initiatives in Uganda, China and the Republic of South Africa to advance the understanding of infection-related cancers and infectious diseases that affect high-risk populations in these regions. VIDD scientists around the world including clinicians, clinical trials specialists, statisticians, computational biologists and basic scientists take pride in their collaborative efforts to predict, detect, treat and prevent infectious diseases in humans.